or antidepressants, the effectiveness of these agents remains inconsistent. Objective: To present the case of a patient displaying apathy after cerebral infarction who was successfully treated for apathy with aripiprazole monotherapy. Case summary: A 56-year-old woman noticed numbness in her left arm and received treatment for cerebral infarction 10 years ago. The numbness was resolved, but she continued to display severe social impairments, including a lack of initiative for housekeeping or loss of motivation for doing anything. When her husband brought her to our hospital, she was lean, disheveled, and dingy, and her verbal responses were prompt but passive. Although she was not depressed, she was assessed as having apathy because of her high score (39) on the Japanese version of Starkstein's Apathy Scale (SAS). We initiated treatment with aripiprazole (3 mg/day) during her hospitalization. After approximately 8 weeks, her SAS score decreased to 21, and she was eventually able to participate in occupational therapy. Psychosocial and environmental support will be added to her treatment regimen because she still has some difficulty maintaining her daily routine. Discussion: The pharmacological mechanism of aripiprazole for apathy treatment remains uncertain. Moreover, it is unclear whether the effectiveness of aripiprazole in this patient can be generalized to other cases of apathy. Conclusion: Because aripiprazole administration was associated with partial improvement in a patient with apathy (after cerebral infarction), this agent may be considered as potential therapy for apathy.
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Long-term safety of adjunctive brexpiprazole Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies.The long-term safety and tolerability of adjunctive treatment with brexpiprazole were evaluated in patients with major depressive disorder and inadequate response to antidepressant treatments, based on pooled data from two open-label extension studies. Methods: These were open-label, 52-and 26-week, flexibledose studies (study 1 [NCT01447576]: 0.25-3mg/day; study 2 [NCT01360866]: 0.5-3mg/day) with brexpiprazole. Study 1 enrolled de novo patients and patients completing one of the two phase II studies (NCT00797966; NCT01052077) while study 2 enrolled patients completing one of the two pivotal phase III studies (NCT01360645 [1] ;NCT01360632 [2] ). Study 2 is still ongoing; data presented are based on a data-cut from 15-May-2015. Results: 2084 patients were enrolled (697 from study 1 and 1387 from study 2); 48.8% (1016/2084) completed 52 weeks of treatment. Mean brexpiprazole dose was 1.6 mg/day. 13.9% (291/2084) of the patients had a TEAE leading to withdrawal; most frequent AEs leading to withdrawal (>1%) were weight increased (3.6%) and depression (1.3%). The two most frequently reported AEs were weight increased (25.5%) and akathisia (10.0%); the AE profile was similar to that observed in the short-term lead-in studies with no indication of an increased incidence over time for any AEs. Mean weight gain was 2.9kg at week 26 (n=1259) and 3.2kg at week 52 (n=1015). 30.3% (629/2077)of patients had a weight increase that was ≥7% in body weight. There were small changes in other metabolic parameters. Conclusion: Long-term adjunctive treatment with brexpiprazole was safe and well tolerated. Although increases in body weight were observed over time for some patients, the low incidence of discontinuation among those patients suggests that the weight gain was not treatment-limiting for most patients.
